Stalevo is a combination of Levodopa which gets converted to dopamine, a chemical messenger that controls movement in the brain. Carbidopa manages the breakdown of Levodopa by allowing it to enter the brain for increased dopamine levels and Entacapone maintains the level of levodopa in the blood. All these collective actions provide greater relief from the symptoms of Parkinson’s disease.
Stalevo 125mg+31.25mg+200mg Tablet combines three active ingredients:
Together, these ingredients provide greater relief from Parkinson's disease symptoms.
Treatment of adult patients with Parkinson's disease experiencing end-of-dose motor fluctuations not stabilized on levodopa/DDC inhibitor treatment.
Adults:
Transferring Patients to Stalevo:
From Levodopa/DDC Inhibitor (Carbidopa or Benserazide) and Entacapone:
From Levodopa/Benserazide and Entacapone:
For Patients Not Currently Treated with Entacapone:
Dose Adjustment During Treatment:
Discontinuation of Stalevo:
Severe hepatic impairment, narrow-angle glaucoma, pheochromocytoma, MAO inhibitors, history of NMS, or hypersensitivity to components.
Store in a cool and dry place away from sunlight
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.